BRENDA home
History
Information on EC 3.4.21.21 - coagulation factor VIIa
for references in articles please use BRENDA:EC3.4.21.21Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.4.21.21 coagulation factor VIIaSpecify your search results
Word Map
- 3.4.21.21
- bleeding
- fibrinogen
- platelet
- viii
-
hemostatic
- hemorrhage
- thrombosis
-
anticoagulant
- thromboplastin
- plasminogen
- haemophilia
- antithrombin
- coagulopathy
- coronary
-
transfusion
- willebrand
-
thromboembolic
- trauma
- fibrin
-
fibrinolysis
-
haemostasis
-
d-dimers
-
antithrombotic
- warfarin
-
hypercoagulable
-
intravascular
- pai-1
-
off-label
-
perioperative
- hematoma
-
k-dependent
-
amidolytic
-
thrombogenic
-
antifibrinolytic
-
tranexamic
-
prothrombotic
-
thrombin-antithrombin
-
plasma-derived
- drug development
- prothrombinase
- epistaxis
- fondaparinux
- desmopressin
-
cryoprecipitate
-
thromboelastometry
- dabigatran
- biotechnology
-
gamma-carboxyglutamic
- menorrhagia
- apixaban
-
thromboelastography
-
bethesda
- medicine
The enzyme appears in viruses and cellular organisms
Synonyms
factor vii, rfviia, fvii, fviia, factor viia, activated factor vii, recombinant factor viia, coagulation factor vii, fviic, novoseven, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
activated blood coagulation factor VII
-
-
-
-
activated factor VII
blood-coagulation factor VII, activated
-
-
-
-
blood-coagulation factor VIIa
-
-
-
-
coagulation factor VII
Eptacog alfa
-
-
-
-
Factor VII
factor VIIa
FVII
FVIIa
Serum prothrombin conversion accelerator
-
-
-
-
tissue factor/factor VIIa
additional information
-
the enzyme is a member of the trypsin family of serine proteases
factor VIIa
-
-
FVIIa
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
Selective cleavage of Arg-/-Ile bond in factor X to form factor Xa
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Phosphorylation
-
phosphorylation of signal transducers and activators of transcription
hydrolysis of peptide bond
-
-
endopeptidase
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
65312-43-8
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
benzoyl-Ile-Glu-gamma-methoxyglutamyl-Gly-Arg-p-nitroanilide + H2O
benzoyl-Ile-Glu-gamma-methoxyglutamyl-Gly-Arg + p-nitroaniline
-
i.e. S2222, 2% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
benzyloxycarbonyl-Arg-p-nitrobenzyl ester + H2O
benzyloxycarbonyl-Arg + 4-nitrophenyl
-
-
-
-
?
benzyloxycarbonyl-D-Arg-Gly-Arg + H2O
?
-
i.e. S2765, 6% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
benzyloxycarbonyl-D-Arg-Gly-Arg-4-nitroanilide + H2O
?
-
chromogenic S-2765
-
-
?
benzyloxycarbonyl-D-arginyl-D-glycyl-D-arginine-p-nitroanilide + H2O
p-nitroaniline + benzyloxycarbonyl-D-arginyl-D-glycyl-D-arginine
-
-
-
-
?
benzyloxycarbonyl-D-arginyl-glycyl-arginine-p-nitroanilide + H2O
benzyloxycarbonyl-D-arginyl-glycyl-arginine + p-nitroaniline
-
-
-
-
?
benzyloxycarbonyl-D-arginyl-glycyl-L-arginyl-p-nitroanilide + H2O
benzyloxycarbonyl-D-arginyl-glycyl-L-arginine + p-nitroaniline
-
-
-
-
?
Chromozym tissue plasminogen activator + H2O
?
-
i.e. N-methylsulfonyl-D-Phe-Gly-Arg-4-nitranilide acetate
-
-
?
D-cyclohexylglycyl-L-2-aminobutyryl-L-arginyl-4-nitroanilide + H2O
D-cyclohexylglycyl-L-2-aminobutyryl-L-arginine + 4-nitroaniline
-
-
-
-
?
D-isoleucyl-L-prolyl-L-arginine-p-nitroanilide + H2O
D-isoleucyl-L-prolyl-L-arginine + p-nitroaniline
-
-
-
-
?
D-phenylalanyl-L-pipecolyl-L-arginine-p-nitroanilide + H2O
D-phenylalanyl-L-pipecolyl-L-arginine + p-nitroaniline
-
-
-
-
?
D-Pro-Phe-Arg-p-nitroanilide + H2O
D-Pro-Phe-Arg + p-nitroaniline
-
i.e. S2302, 12% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
Eph tyrosine kinase receptor EphA2 + H2O
?
-
cleavage site at the Arg159-His160 bond
-
-
?
Eph tyrosine kinase receptor EphB2 + H2O
?
-
cleavage site at the Arg159-His160 bond
-
-
?
factor VIII + H2O
factor VIIIa + ?
-
FVIII activity increases about 4-fold within 30 s in the presence of FVIIa/tissue factor. The heavy chain of FVIII is proteolyzed at Arg336. Arg740 and Arg372
-
-
?
H-D-isoleucyl-L-prolyl-arginine-p-nitroanilide + H2O
H-D-isoleucyl-L-prolyl-arginine + p-nitroaniline
-
i.e. S-2288
-
-
?
methanesulfonyl-D-cyclohexylalanyl-butyl-arginine p-nitroanilide + H2O
methanesulfonyl-D-cyclohexylalanyl-butyl-arginine + p-nitroaniline
-
-
-
-
?
N-acetyl-Ala-P3-P2-Lys-7-amido-4-carbamoylmethylcoumarin + H2O
?
-
P2: Val or Thr, P3: Gln, Arg, Asn or Pro
-
-
?
N-methoxycarbonyl-D-Nle-Gly-Arg-p-nitroanilide + H2O
N-methoxycarbonyl-D-Nle-Gly-Arg + p-nitroaniline
-
i.e. chromozym X, 11% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
N-methylsulfonyl-D-Phe-Gly-Arg-4-nitroanilide + H2O
N-methylsulfonyl-D-Phe-Gly-Arg + 4-nitroaniline
-
-
-
?
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide + H2O
N-methylsulfonyl-D-Phe-Gly-Arg + p-nitroaniline
N-methylsulfonyl-D-phenyl-D-glycyl-D-arginyl-4-nitroanilide + H2O
N-methylsulfonyl-D-phenyl-D-glycyl-D-arginine + 4-nitroaniline
-
-
-
?
pyroglutamyl-Gly-Arg-p-nitroanilide + H2O
pyroglutamyl-Gly-Arg + p-nitroaniline
-
i.e. S2444, 2% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
pyroglutamyl-Phe-Lys-p-nitroanilide + H2O
pyroglutamyl-D-Phe-Gly-Arg + p-nitroaniline
-
i.e. S2403, 1.4% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
pyroglutamyl-Pro-Arg-p-nitroanilide + H2O
pyroglutamyl-Pro-Arg + p-nitroaniline
-
i.e. S2366, 38% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
signal transducer and activator of transcription 5 + ?
activated signal transducer and activator of transcription 5 + ?
-
STAT5
-
-
?
Z-D-arginyl-glycyl-arginine-p-nitroanilide + H2O
Z-D-arginyl-glycyl-arginine + p-nitroaniline
-
-
-
-
?
D-Ile-Pro-Arg-4-nitroanilide + H2O
D-Ile-Pro-Arg + 4-nitroaniline
-
-
-
?
D-Ile-Pro-Arg-4-nitroanilide + H2O
D-Ile-Pro-Arg + 4-nitroaniline
-
chromogenic substrate S-2288
-
-
?
D-Ile-Pro-Arg-4-nitroanilide + H2O
D-Ile-Pro-Arg + 4-nitroaniline
S-2288
-
-
?
D-Ile-Pro-Arg-p-nitroanilide + H2O
D-Ile-Pro-Arg + p-nitroaniline
-
i.e. S2288
-
-
?
D-Ile-Pro-Arg-p-nitroanilide + H2O
D-Ile-Pro-Arg + p-nitroaniline
-
i.e. S2288, 68% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
D-Phe-pipecolyl-Arg-p-nitroanilide + H2O
D-Phe-pipecolyl-Arg + p-nitroaniline
-
-
-
-
?
D-Phe-pipecolyl-Arg-p-nitroanilide + H2O
D-Phe-pipecolyl-Arg + p-nitroaniline
-
i.e. S2238, 34% of the activity with N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide, plasma-derived wild-type enzyme
-
-
?
factor X + H2O
activated factor X + ?
-
the enzyme initiates blood clotting after interacting with its cofactor tissue factor. The product of the reaction, activated factor X, is also the most efficient activator of zymogen factor VII
-
-
?
factor X + H2O
factor Xa
-
-
-
-
?
Factor X + H2O
Factor Xa + ?
-
-
683347, 683477, 683855, 717385, 731271, 732085, 752660, 752758, 753091, 754519, 755008, 755547, 755589
-
-
?
Factor X + H2O
Factor Xa + ?
-
the enzyme is involved in the coagulation cascade, pathways, overview
-
-
?
Factor X + H2O
Factor Xa + ?
-
FX cleavage site Asn-Leu-Thr-Ar-/-Ile-Val-Gly-Gly
-
-
?
Factor X + H2O
Factor Xa + ?
-
macromolecular substrate interactions at exosites, sites within the FVIIa-TF complex distant from the active site of FVIIa, determine affinity and specificity in the productive recognition of FX
-
-
?
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide + H2O
N-methylsulfonyl-D-Phe-Gly-Arg + p-nitroaniline
-
-
-
-
?
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide + H2O
N-methylsulfonyl-D-Phe-Gly-Arg + p-nitroaniline
-
i.e. chromozym t-PA
-
-
?
protease-activated receptor 2 + H2O
?
-
protease-activated receptor 2 is cleaved by FVIIa in the binary tissue factor-FVIIa complex
-
-
?
thrombinogen + H2O
thrombin + ?
-
antifibrinolytic effect of the enzyme in relation to the activity of thrombin, regulation, overview
-
-
?
additional information
?
-
-
factor VIIa initiates the coagulation pathway upon complex formation with its cellular receptor and cofactor tissue factor
-
-
?
additional information
?
-
-
blood coagulation is initiated when tissue factor binds to coagulation factor VII to give an enzymatically active complex which then activates factors IX and X, leading to thrombin generation and clot formation
-
-
?
additional information
?
-
the enzyme plays a key role in the blood coagulation cascade
-
-
?
additional information
?
-
-
the enzyme plays a key role in the blood coagulation cascade
-
-
?
additional information
?
-
-
cell-surface tissue factor TF binds the serine protease factor VIIa to activate coagulation or, alternatively, to trigger signaling through the G protein-coupled, protease-activated receptor 2 relevant to inflammation and angiogenesis, TF-VIIa-mediated coagulation and cell signaling involve distinct cellular pools of TF, regulation, overview
-
-
?
additional information
?
-
-
membrane binding constitutes a key process in enzymatic activation of various blood coagulation factors
-
-
?
additional information
?
-
-
a loop of factor VIIa influences the macromolecular substrate specificity, overview
-
-
?
additional information
?
-
-
structure-function relationship, the enzyme forms a complex with the cell surface receptor tissue factor TF required for attaining its catalytically competent conformation, Asp338 is a catalytically important residue
-
-
?
additional information
?
-
-
substrate and cleavage site specificity with 7-amino-4-carbamoylmethylcoumarin-linked tetrapeptides, specificity profiling of the recombinant enzyme, overview
-
-
?
additional information
?
-
complex formation with the essential protein cofactor tissue factor
-
-
?
additional information
?
-
-
enzyme blood coagulation activity is regulated in the circadian clock machinery, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
Eph tyrosine kinase receptor EphA2 + H2O
?
-
cleavage site at the Arg159-His160 bond
-
-
?
Eph tyrosine kinase receptor EphB2 + H2O
?
-
cleavage site at the Arg159-His160 bond
-
-
?
factor VIII + H2O
factor VIIIa + ?
-
FVIII activity increases about 4-fold within 30 s in the presence of FVIIa/tissue factor. The heavy chain of FVIII is proteolyzed at Arg336. Arg740 and Arg372
-
-
?
factor X + H2O
activated factor X + ?
-
the enzyme initiates blood clotting after interacting with its cofactor tissue factor. The product of the reaction, activated factor X, is also the most efficient activator of zymogen factor VII
-
-
?
Factor X + H2O
Factor Xa + ?
-
-
-
-
?
Factor X + H2O
Factor Xa + ?
-
the enzyme is involved in the coagulation cascade, pathways, overview
-
-
?
protease-activated receptor 2 + H2O
?
-
protease-activated receptor 2 is cleaved by FVIIa in the binary tissue factor-FVIIa complex
-
-
?
thrombinogen + H2O
thrombin + ?
-
antifibrinolytic effect of the enzyme in relation to the activity of thrombin, regulation, overview
-
-
?
additional information
?
-
-
factor VIIa initiates the coagulation pathway upon complex formation with its cellular receptor and cofactor tissue factor
-
-
?
additional information
?
-
-
blood coagulation is initiated when tissue factor binds to coagulation factor VII to give an enzymatically active complex which then activates factors IX and X, leading to thrombin generation and clot formation
-
-
?
additional information
?
-
the enzyme plays a key role in the blood coagulation cascade
-
-
?
additional information
?
-
-
the enzyme plays a key role in the blood coagulation cascade
-
-
?
additional information
?
-
-
cell-surface tissue factor TF binds the serine protease factor VIIa to activate coagulation or, alternatively, to trigger signaling through the G protein-coupled, protease-activated receptor 2 relevant to inflammation and angiogenesis, TF-VIIa-mediated coagulation and cell signaling involve distinct cellular pools of TF, regulation, overview
-
-
?
additional information
?
-
-
membrane binding constitutes a key process in enzymatic activation of various blood coagulation factors
-
-
?
additional information
?
-
complex formation with the essential protein cofactor tissue factor
-
-
?
additional information
?
-
-
enzyme blood coagulation activity is regulated in the circadian clock machinery, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
additional information
complex formation with the essential protein cofactor tissue factor
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Ca2+
Mg2+
Mg2+ potentiates the activation of factor X and factor IX by factor VIIa
additional information
-
Mg2+ alone does not significantly influence the rate of factor X activation by the enzyme. The presence of tissue factor is required for Mg2+ to enhance the rate of factor X activation by the enzyme
Ca2+
bound to the backbone-carbonyl groups of Asp72 and Glu75, and to the side-chain carboxylate groups of Glu70 and Glu80
Ca2+
-
dependent on, eight Ca2+ are bound via the Gla domain and involved in enzyme binding to the membrane with different tasks, structure and coordination, mechanism of Ca2+-mediated binding, overview
Ca2+
-
one FVIIa molecule binds 8 Ca2+ in the epidermal growth factor-like and the gamma-carboxyglutamic acid-rich domains
Ca2+
Ca2+ ions constitute an important cofactor for FVIIa and bind to a total of nine sites, seven in the N-terminal gamma-carboxyglutamic acid (Gla) domain and one each in the first EGF-like and protease domains
Ca2+
-
the enzyme binds the phospholipid membrane in a Ca2+-dependent manner. Ca2+ ions are required for assembly and function of the tissue factor-enzyme complex
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(2R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
-
-
(2R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-(propane-2-sulfonyl)-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
-
-
(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-7-(cyclopropanesulfonyl)-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo-[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione
-
highly potent, selective inhibitor
(2R,15R)-2-[(1-amino-7-fluoroisoquinolin-6-yl)amino]-7-(cyclopropanesulfonyl)-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo-[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione
-
-
(2R,15R)-2-[(1-amino-8-fluoroisoquinolin-6-yl)amino]-7-(cyclopropanesulfonyl)-4,15,17- trimethyl-13-oxa-4,11-diazatricyclo-[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione
-
-
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10-(21),16,19-hexaene-3,12-dione
-
-
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11- diazatricyclo[14.2.2.16,10]henicosa-1-(18),6,8,10(21),16,19-hexaene-7-carboxamide
-
-
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-7-(trifluoromethoxy)-13-oxa-4,11-diazatricyclo[14.2.2.16,10]-henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione
-
-
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,20-trimethyl-7-(1-methyl-1H-pyrazol-5-yl)-13-oxa-4,11-diazatricyclo-[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione
-
-
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-(cyclopropanesulfonyl)-4,15,20-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]-henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione
-
-
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-N,N,4,15,17-pentamethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]-henicosa-1(18),6,8,10(21),16,19-hexaene-7-carboxamide
-
-
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-N,N-diethyl-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]-henicosa-1(18),6,8,10(21),16,19-hexaene-7-carboxamide
-
-
(2S)-2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
-
-
(R)-2-(1-aminoisoquinolin-6-ylamino)-7-ethanesulfonyl-20-methyl-4,11-diaza-tricyclo[14.2.2.16,10]henicosa-1(19),6,8,10-(21),16(20),17-hexaene-3,12-dione
-
-
(R)-2-(1-aminoisoquinolin-6-ylamino)-7-ethanesulfonyl-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(19),6,8,10(21),16-(20),17-hexaene-3,12-dione
-
-
([5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]methyl)propanedioic acid
-
-
2-(1-aminoisoquinolin-6-ylamino)-16-oxa-4,11-diazatricyclo-[15.2.2.16,10]docosa-1(20),6,8,10(22),17(21),18-hexaene-3,12-dione trifluoroacetic acid
-
-
2-(3'-amino-3-fluoro-4-(isopropylamino)-1,1'-biphenyl-2-yl)-N-(4-(amino(imino)methyl)benzyl)acetamide
-
IC50: 340 nM
2-(3'-amino-4-(benzylamino)-3-fluoro-1,1'-biphenyl-2-yl)-N-(4-(amino(imino)methyl)benzyl)acetamide
-
IC50: 500 nM
2-(3-allylamino-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 700 nM
2-(3-benzylamino-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 770 nM
2-(3-benzylsulfanyl-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 0.0064 mM
2-(3-butylamino-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 0.0032 mM
2-([5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-5'-fluoro-2',6-dihydroxybiphenyl-3-yl]methyl)butanedioic acid
-
-
2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[13.2.2.16,10]icosa-1(17),6(20),7,9,15,18-hexaene-3,12-dione
-
-
2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
-
-
2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[15.2.2.16,10]docosa-1(19),6(22),7,9,17,20-hexaene-3,12-dione
-
-
2-[3-(2-amino-ethylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 0.0021 mM
2-[3-(3-amino-propylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 890 nM
2-[3-(4-amino-butylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 980 nM
2-[3-(4-tert-butyl-cyclohexylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 0.003 mM
2-[3-(adamantan-1-ylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 0.013 mM
2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-5'-fluoro-2',6-dihydroxybiphenyl-3-yl]butanedioic acid
-
-
2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]butanedioic acid
-
-
2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]pentanedioic acid
-
-
2-[5-(5-carbamimidoyl-1H-indol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]butanedioic acid
-
-
2-[6-(3-acetylamino-phenyl)-5-chloro-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 0.00161 mM
2-[6-(3-amino-phenyl)-5-chloro-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 70 nM
2-[6-(3-amino-phenyl)-5-chloro-3-cyclobutylamino-2-oxo-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 20 nM
2-[6-(3-amino-phenyl)-5-chloro-3-isopropylamino-2-oxo-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 20 nM
2-[6-(3-bromo-phenyl)-5-chloro-3-cyclobutylamino-2-oxo-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
-
pH 8.0, IC50: 0.0042 mM
3-(3-[(R)-2-[(S)-1-(4-carbamimidoyl-benzylcarbamoyl)-3-carbamoylpropylcarbamoyl]-2-ethanesulfonylamino-ethyl]-1H-indol-5-yloxymethyl)-benzoic acid
-
3-amino-5-(1-(1-((4-(amino(imino)methyl)benzyl)-amino)-2-oxoethyl)-5-(isopropylamino)-6-oxo-1,6-dihydropyridin-2-yl)benzoic acid
-
IC50: 118 nM
3-amino-5-[1-[2-([4-[amino(imino)methyl]benzyl]amino)-2-oxoethyl]-3-chloro-5-(isopropylamino)-6-oxo-1,6-dihydropyrazin-2-yl]benzoic acid
-
pH 8.0, IC50: 16 nM, potent and highly selective inhibitor, selectivity versus factor Xa and thrombin
3-methyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-pentanoic acid [4-guanidino-1-(thiazole-2-carbonyl)-butyl]-amide
-
IC50: 300 nM, reversible, covalent
3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00145 mM, reversible, covalent
3-[1-[(4-carbamimidoyl-benzylcarbamoyl)-methyl]-3-chloro-5-isopropylamino-6-oxo-1,6-dihydro-pyrazin-2-yl]-benzoic acid
-
pH 8.0, IC50: 360 nM
3-[1-[(4-carbamimidoyl-benzylcarbamoyl)-methyl]-3-chloro-5-isopropylamino-6-oxo-1,6-dihydro-pyrazin-2-yl]-benzoic acid methyl ester
-
pH 8.0, IC50: 780 nM
3-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]pentanedioic acid
-
-
3-[5-(5-carbamimidoyl-1H-indol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]pentanedioic acid
-
-
4,4-dimethyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-pentanoic acid [4-guanidino-1-(thiazole-2-carbonyl)-butyl]-amide
-
IC50: 700 nM, reversible, covalent
4-((R)-7-ethanesulfonyl-3,12-dioxo-4,11-diaza-tricyclo-[14.2.2.16,10]henicosa-1(19),6,8,10(21),16(20),17-hexaen-2-ylamino)benzamidine trifluoroacetic acid
-
-
4-[5-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]-1H-imidazol-4-yl]pyridine
-
-
5-(4-carboxybutoxy)-N-(ethylsulfonyl)-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
-
5-[(3-carboxybenzyl)oxy]-N-(ethylsulfonyl)-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
-
6-dimethylamino-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-hexanoic acid [4-guanidino-1-(thiazole-2-carbonyl)-butyl]-amide
-
IC50: 0.00282 mM, reversible, covalent
Bovine pancreatic trypsin inhibitor
-
mutant enzyme K192E is poorly inhibited, mutant enzyme K192Q is inhibited more than the wild-type enzyme
-
diethyl [(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl]phosphonate
-
-
dimeric active site-inhibited blood clotting factor VIIa
-
dimeric fVIIai, 16000fold inhibitory effect
-
FFR-FVIIa
-
derivate of FVIIa with a stably buried N-terminus representing the active conformation of FVIIa, IC50: 0.019 mM
-
methyl (2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-7-carboxylate
-
-
N-(3-[1-[(4-carbamimidoyl-benzylcarbamoyl)-methyl]-3-chloro-6-oxo-5-phenethylamino-1,6-dihydro-pyrazin-2-yl]-phenyl)-2,2,2-trifluoro-acetamide
-
pH 8.0, IC50: 450 nM
N-(4-(amino(imino)methyl)benzyl)-2-(2,6-difluoro-3-((2-phenylethyl)amino)phenyl)acetamide
-
IC50: 0.0164 mM
N-(4-(amino(imino)methyl)benzyl)-2-(3-fluoro-4-((2-phenylethyl)amino)-1,1'-biphenyl-2-yl)acetamide
-
IC50: 0.00398 mM
N-(4-(amino(imino)methyl)benzyl)-2-(3-hydroxy-4-((2-phenylethyl)amino)-1,1'-biphenyl-2-yl)acetamide
-
IC50: 0.0027 mM
N-(4-(amino(imino)methyl)benzyl)-2-(3-hydroxy-4-(isopropylamino)-1,1'-biphenyl-2-yl)acetamide
-
IC50: 0.0025 mM
N-(4-(amino(imino)methyl)benzyl)-2-(3-methoxy-4-((2-phenylethyl)amino)-1,1'-biphenyl-2-yl)acetamide
-
IC50: 0.025 mM
N-(4-(amino(imino)methyl)benzyl)-2-(4-(isopropylamino)-3-methoxy-1,1'-biphenyl-2-yl)acetamide
-
IC50: 0.0147 mM
N-(4-(amino(imino)methyl)benzyl)-2-(5-(isopropylamino)-3,6-dioxo-2-phenylcyclohexa-1,4-dien-1-yl)acetamide
-
IC50: 0.0028 mM
N-(4-(amino(imino)methyl)benzyl)-2-(6-(3,5-diaminophenyl)-3-(isopropylamino)-2-oxopyridin-1(2H)-yl)acetamide
-
IC50: 52 nM
N-(4-carbamimidoyl-benzyl)-2-(2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 340 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-m-tolyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.001 mM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-o-tolyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 430 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-p-tolyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.00414 mM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 630 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-phenylamino-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.0112 mM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-prop-2-ynylamino-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 720 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-propylamino-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 400 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-pyrrolidin-1-yl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.0063 mM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-cyclobutylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 400 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-cyclohexylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.0014 mM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-ethylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 400 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-isopropylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 200 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-methylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 700 nM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-6-ethyl-2-oxo-3-phenethylamino-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.00345 mM
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-6-methyl-2-oxo-3-phenethylamino-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.00428 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-3-phenethylamino-6-(2-trifluoromethyl-phenyl)-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0027 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-3-phenethylamino-6-(3-trifluoromethyl-phenyl)-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0029 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(1-propyl-butylamino)-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0018 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(3-phenyl-propylamino)-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0126 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(3-trifluoromethyl-benzylamino)-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0063 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(4-phenyl-butylamino)-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0041 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1,1-dioxo-tetrahydro-16-thiophen-3-ylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.001 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-ethyl-hexylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0098 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-ethyl-propylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 430 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-methyl-butylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 840 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-methyl-pentylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 900 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2,5-difluoro-benzylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0038 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-dimethylamino-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0209 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-hydroxy-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 500 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-methoxy-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 880 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-morpholin-4-yl-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.008 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(3,5-difluoro-benzylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.006 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(3-dimethylamino-propylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0176 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(3-hydroxy-propylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 500 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(4-chloro-benzylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0043 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(4-hydroxy-butylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 600 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(6-hydroxy-hexylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 470 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(isopropyl-methyl-amino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0091 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-cyclobutylamino-6-(2-hydroxy-phenyl)-2-oxo-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 340 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-cyclobutylamino-6-(3-hydroxy-phenyl)-2-oxo-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 200 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(2-chloro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.003 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(2-fluoro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0018 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(2-methoxy-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0016 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-chloro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.00198 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-dimethylamino-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0012 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-fluoro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0023 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-methanesulfonylamino-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 600 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-methoxy-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0052 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-methylamino-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 600 nM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-nitro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.00252 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(4-chloro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.00888 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(4-fluoro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.0081 mM
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(4-methoxy-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
-
pH 8.0, IC50: 0.02345 mM
N-(4-carbamimidoyl-benzyl)-2-{5-chloro-2-oxo-6-phenyl-3-[2-(3-trifluoromethyl-phenyl)-ethylamino]-2H-pyrazin-1-yl}-acetamide
-
pH 8.0, IC50: 0.03 mM
N-(4-carbamimidoyl-benzyl)-2-{5-chloro-3-[2-(3-chloro-phenyl)-ethylamino]-2-oxo-6-phenyl-2H-pyrazin-1-yl}-acetamide
-
pH 8.0, IC50: 180 nM
N-(4-carbamimidoyl-benzyl)-2-{5-chloro-3-[2-(4-chloro-phenyl)-ethylamino]-2-oxo-6-phenyl-2H-pyrazin-1-yl}-acetamide
-
pH 8.0, IC50: 600 nM
N-(5-carbamimidoyl-pyridin-2-ylmethyl)-2-(2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.0167 mM
N-(6-carbamimidoyl-pyridin-3-ylmethyl)-2-(2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
-
pH 8.0, IC50: 0.0014 mM
N-(ethylsulfonyl)-1-methyl-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
-
N-(ethylsulfonyl)-5-hydroxy-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
-
N-(ethylsulfonyl)-5-methoxy-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
-
N-(ethylsulfonyl)-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-L-glutamamide
-
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(3,4,5-trifluoro-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 200 nM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(3-trifluoromethyl-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 800 nM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(4-iodo-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00156 mM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(4-nitro-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00588 mM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-hydroxy-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 110 nM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-m-tolyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 170 nM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-naphthalen-1-yl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.0056 mM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-naphthalen-2-yl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00195 mM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-o-tolyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 240 nM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-p-tolyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00129 mM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-phenyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 42 nM, reversible, covalent
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-pyridin-3-yl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 200 nM, reversible, covalent
N-[2-(1-benzyl-1H-imidazol-4-yl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00997 mM, reversible, covalent
N-[2-(2,6-dimethyl-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 700 nM, reversible, covalent
N-[2-(2-fluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 90 nM, reversible, covalent
N-[2-(3,4-difluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 160 nM, reversible, covalent
N-[2-(3,5-difluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 190 nM, reversible, covalent
N-[2-(3-chloro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 230 nM, reversible, covalent
N-[2-(3-fluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 200 nM, reversible, covalent
N-[2-(4-acetylamino-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 570 nM, reversible, covalent
N-[2-(4-bromo-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 760 nM, reversible, covalent
N-[2-(4-chloro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 680 mM, reversible, covalent
N-[2-(4-cyano-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 340 nM, reversible, covalent
N-[2-(4-fluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 170 nM, reversible, covalent
N-[2-benzo[b]thiophen-3-yl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.0005 mM, reversible, covalent
N-[2-benzyloxy-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00153 mM, reversible, covalent
N-[2-biphenyl-3-yl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.00183 mM, reversible, covalent
N-[2-biphenyl-4-yl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.0178 mM, reversible, covalent
N-[2-cyclohexyl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 0.0033 mM, reversible, covalent
N-[2-cyclopropyl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
-
IC50: 820 nM, reversible, covalent
N-[3-[(2R)-1-[(2R)-2-[(1-aminoisoquinolin-6-yl)amino]-2-phenylacetyl]pyrrolidin-2-yl]-4-(propane-2-sulfonyl)phenyl]acetamide
-
-
N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-3-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-succinamic acid cyclohexyl ester
-
IC50: 0.00318 mM, reversible, covalent
N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-4-methanesulfonyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-butyramide
-
IC50: 0.0137 mM, reversible, covalent
N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-4-phenyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-butyramide
-
IC50: 900 nM, reversible, covalent
N1-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-succinamide
-
IC50: 0.00103 mM, reversible, covalent
R-4-[2-(3-aminobenzenesulfonylamino)-1-(3,5-diethoxy-2-fluorophenyl)-2-oxoethylamino]-2-hydroxy-benzamidine
incubation with enzyme in 100 mM Hepes, pH 7.8, 140 mM NaCl, 0.1% (v/v) polyethylene glycol 8000, 0.02% (v/v) Tween 80, 5 mM CaCl2 for 40 min at room temperature
V154G-FVIIa
-
derivate of FVIIa with a fully exposed N-terminus representing the zymogen-like conformation of FVIIa, IC50: 0.014 mM
-
Zn2+
-
two Zn2+ bind with high affinity to factor VIIa outside the N-terminal gamma-carboxyglutamic acid domain. Binding of Zn2+ is influenced by presence of Ca2+ and results in decreased amidolytic activity and slightly reduced affinity for tissue factor. After binding to tissue factor, factor VIIa is less susceptible to zinc inhibition
[(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,20-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1-(18),6,8,10(21),16,19-hexaen-7-yl](ethoxy)phosphinic acid
-
-
[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-5'-fluoro-2',6-dihydroxybiphenyl-3-yl]acetic acid
-
-
[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]acetic acid
-
-
[5-(5-carbamimidoyl-1H-indol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]acetic acid
-
-
antithrombin
-
in presence of heparin, 20% loss of activity of wild-type enzyme after 15 min, 59% loss of activity of the K337A mutant enzyme after 15 min, 77% loss of activity of the L305V/K337A mutant enzyme after 15 min, 78% loss of activity of the V158D/D296V/M298Q mutant enzyme after 15 min, 87% loss of activity of the V158D/D296V/M298Q/K337A mutant enzyme after 15 min, 91% loss of activity of the V158D/D296V/M298Q/L305V/K337A mutant enzyme after 15 min, 53% loss of activity of the M298Q mutant enzyme after 15 min
-
antithrombin
-
0.1 mg/ml in the presence of 1 unit/ml heparin, less than 10% residual activity after 15min incubation with enzyme FVIIa-sTF
-
antithrombin
-
can inhibit factor VIIa effectively only when it is bound to tissue factor
-
EEWEVLCWTWETCER
-
IC50: 1.6 nM, partial hyperbolic mixed-type inhibitor of factor X activation, partial competitive inhibitor of amidolytic activity. Inhibits activation of factor X and factor IX and amidolytic activity of Chromozym t-PA with IC50 values of 1.6 nM, 3.5 nM and 8.5 nM
tissue factor pathway inhibitor
-
no inhibition of the mutant enzymes K192E and K192Q
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Herpes simplex virus 1 encoded glycoprotein C
-
gC, 1000fold activity-enhancing effect in the absence of tissue factor and in the presence of 5 mM Ca2+ and 0.1 mM synthetic small unilamellar vesicles composed of 75% phosphatidylcholine and 25% phosphatidylserine
-
phospholipid vesicle
-
oleoyl-1,2-diacyl-sn-glycero-3-phosphocholine and dioleoyl-1,2-diacyl-sn-glycero-3-(phospho-L-serine)
-
tissue factor TF
-
TF-induced allosteric activation of FVIIa, binding structure, overview
-
tissue factor
-
factor VIIa remains in a zymogen-like state following proteolytic activation and depends on interactions with the cofactor tissue factor for function. Val21, Glu154 and Met156 cooperate to stabilize the conformation of the enzyme and to enhance the affinity for tissue factor
-
tissue factor
-
the enzyme initiates blood clotting after interacting with its cofactor tissue factor. Soluble tissue factor concentrations of 5.0 nM and 22.4 nM for the activated wild-type factor VII and for the mutant form A294V of the activated wild-type factor yield an activity of 50% towards spectrozyme fVIIa
-
tissue factor
-
tissue factor binding to factor VIIa allosterically augments the enzymatic activity of factor VIIa towards macromolecular substrates and small peptidyl substrates. Tissue factor binding to factor VIIa alters the chemical environment of the active site of factor VIIa by protecting Ile153 from deprotonation in the free enzyme while deprotecting the catalytic triad as a whole when in the Michaelis complex
-
tissue factor
-
cell-surface tissue factor TF binds the serine protease factor VIIa to activate coagulation or, alternatively, to trigger signaling through the G protein-coupled, protease-activated receptor 2 relevant to inflammation and angiogenesis, extracellular Cys186-Cys209 disulfide bond of TF is critical for coagulation, overview, mutant TF C209A with an unpaired Cys186 retains TF-VIIa signaling activity, and it has reduced affinity for VIIa, regulation, overview
-
tissue factor
-
required to attain full catalytic competency and to initiate blood coagulation, mechanism of TF allosterical activation of FVIIa, structural dynamics approach that combines molecular dynamics simulations and hydrogen/deuterium exchange mass spectrometry on free and TF-bound FVIIa, TF structures involved are activation loop 3 residues 365-374/216-225 of the so-called activation domain and the 170-loop residues 313-322/170A-175, overview
-
tissue factor
-
formation of a complex between factor VIIa and tissue factor is necessary to enhance the procoagulant activity of factor VIIa, not only by providing membrane localization, substrate exosites and positioning the active site at an appropriate distance above the surface but also by allosteric enhancement of the enzymatic activity, and this event signals initiation of blood coagulation
-
tissue factor
-
in the absence of its cofactor tissue factor, coagulation factor VIIa predominantly exists in a zymogen-like, catalytically incompetent state
-
tissue factor
-
binding of tissue factor with factor FVIIa only partially enhances the enzyme's proteolytic activity. Soluble tissue factor has a lower binding capacity with the enzyme compared to membrane bound full-length tissue factor
-
tissue factor
-
tissue factor allosterically activates factor VIIa by several mechanisms such as active site positioning, spatial stabilization, and direct interactions with the substrate
-
additional information
-
enzyme activation involves residue 343, mechanisms, overview
-
additional information
-
the relative catalytic efficiency is increased 170 and 150fold in the presence of saturating amounts of monoclonal antibodies F36 and F37, respectively
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.67
methanesulfonyl-D-cyclohexylalanyl-butyl-arginine p-nitroanilide
-
wild-type enzyme
11.8
S-2288
-
in 50 mM HEPES, pH 7.4, with 0.1 M NaCl, 5 mM CaCl2, 0.1% (w/v) bovine serum albumin, and 0.01% Tween 80, at 37°C
7.1
D-Ile-Pro-Arg-4-nitroanilide
mutant G372A + soluble tissue factor for induced allosteric activation of factor VIIa, pH 7.4
1.8
D-Ile-Pro-Arg-4-nitroanilide
wild-type FVIIa + soluble tissue factor for induced allosteric activation of factor VIIa
1.2
D-Ile-Pro-Arg-4-nitroanilide
wild type enzyme, in the presence of soluble tissue factor (1-219), at pH 7.4 and 25°C
8.9
D-Ile-Pro-Arg-4-nitroanilide
wild type enzyme, in the absence of soluble tissue factor (1-219), at pH 7.4 and 25°C
1.43
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, activated wild-type enzyme, activated by tissue factor
1.73
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, mutant enzyme which has all of the residues of the loop formed by a disulfide bond between Cys310 and Cys329 replaced with those of trypsin, activated by tissue factor
1.25
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, plasma derived wild-type enzyme, activated by tissue factor
2.22
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, activated wild-type enzyme, without tissue factor
1.53
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, mutant enzyme DELTA360-329, without tissue factor
2.82
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, plasma derived wild-type enzyme, without tissue factor
2.98
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, mutant enzyme DELTA360-329, activated by tissue factor
3.06
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, mutant enzyme which has all of the residues of the loop formed by a disulfide bond between Cys310 and Cys329 replaced with those of trypsin, without tissue factor
0.0019
Factor X
wild-type FVIIa + soluble tissue factor for induced allosteric activation of factor VIIa, pH 7.4
-
0.0032
Factor X
mutant G372A + soluble tissue factor for induced allosteric activation of factor VIIa, pH 7.4
-
0.0153
Factor X
-
mutant enzyme K192A, tissue factor/phosphatidylcholine vesicles
-
0.0054
Factor X
-
in 50 mM HEPES, pH 7.4, with 0.1 M NaCl, 5 mM CaCl2, 0.1% (w/v) bovine serum albumin, and 0.01% Tween 80, at 25°C
-
0.0207
Factor X
-
mutant enzyme L144A, tissue factor/phosphatidylcholine vesicles
-
0.000015
Factor X
wild-type FVIIa + lipidated tissue factor for induced allosteric activation of factor VIIa, pH 7.4
-
0.0124
Factor X
-
wild-type enzyme VIIa, tissue factor/phosphatidylcholine vesicles
-
0.000043
Factor X
-
mutant enzyme L144A, tissue factor/phosphatidylcholine-phosphatidylserine vesicles
-
0.000051
Factor X
-
mutant enzyme L192A, tissue factor/phosphatidylcholine-phosphatidylserine vesicles
-
0.000059
Factor X
-
mutant enzyme E154A, tissue factor/phosphatidylcholine-phosphatidylserine vesicles
-
0.000069
Factor X
-
wild-type enzyme VIIa, tissue factor/phosphatidylcholine-phosphatidylserine vesicles
-
0.000012
Factor X
mutant G372A + lipidated tissue factor for induced allosteric activation of factor VIIa, pH 7.4
-
2
H-D-isoleucyl-L-prolyl-arginine-p-nitroanilide
-
mutant enzyme L280I/V299M-FVIIa, in the presence of tissue factor, pH 7.4
2.2
H-D-isoleucyl-L-prolyl-arginine-p-nitroanilide
-
mutant enzyme C164V/V299C FVIIa, in the presence of tissue factor, pH 7.4
1.5
H-D-isoleucyl-L-prolyl-arginine-p-nitroanilide
-
wild type enzyme, in the presence of tissue factor, pH 7.4
2.3
H-D-isoleucyl-L-prolyl-arginine-p-nitroanilide
-
mutant enzyme V299M-FVIIa, in the presence of tissue factor, pH 7.4
9.8
H-D-isoleucyl-L-prolyl-arginine-p-nitroanilide
-
mutant enzyme V299M-FVIIa, pH 7.4
6.6
H-D-isoleucyl-L-prolyl-arginine-p-nitroanilide
-
mutant enzyme L280I/V299M-FVIIa, pH 7.4
9.2
H-D-isoleucyl-L-prolyl-arginine-p-nitroanilide
-
mutant enzyme C164V/V299C, pH 7.4
0.9
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, mutant enzyme V21N/E154I/M156Q, with addition of tissue factor
2.2
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 6.5, MTE buffer, without tissue factor
8
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 7.5, HEPES buffer, without tissue factor
0.8
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, wild-type enzyme, with addition of tissue factor
3.1
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, mutant enzyme V21N/E154I/M156Q, without tissue factor
5.3
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, 37°C, mutant enzyme M156Q
10
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 7.5, MTE buffer, without tissue factor
1.2
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, 37°C, mutant enzyme M156Q, addition of tissue factor
2.3
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 6.5, MES buffer, without tissue factor
6.8
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 9.5, ethanolamine buffer, without tissue factor
1.1
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, 37°C, wild-type enzyme, addition of tissue factor
50
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 9.5, veronal buffer, without tissue factor
6.4
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 9.5, BTP buffer, without tissue factor
6.3
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 7.5, Tris buffer, without tissue factor
13
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 9.5, MTE buffer, without tissue factor
5.5
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, wild-type enzyme, without tissue factor
additional information
additional information
-
the KM-value for spectrozyme fVIIa for the mutant enzyme A294V is above 2.5 mM
-
additional information
additional information
-
the ratio of turnover number to KM-value for the substrate methanesulfonyl-D-cyclohexylalanyl-butyl-arginine p-nitroanilide is 25000 for wild-type enzyme, 500 for mutant enzyme V154G and 2500 for mutant enzyme V154A
-
additional information
additional information
-
kinetics of wild-type and mutant enzymes with different substrates, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
17
methanesulfonyl-D-cyclohexylalanyl-butyl-arginine p-nitroanilide
-
wild-type enzyme
13
S-2288
-
in 50 mM HEPES, pH 7.4, with 0.1 M NaCl, 5 mM CaCl2, 0.1% (w/v) bovine serum albumin, and 0.01% Tween 80, at 37°C
7.7
D-Ile-Pro-Arg-4-nitroanilide
wild type enzyme, in the absence of soluble tissue factor (1-219), at pH 7.4 and 25°C
34.6
D-Ile-Pro-Arg-4-nitroanilide
wild type enzyme, in the presence of soluble tissue factor (1-219), at pH 7.4 and 25°C
0.59
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, mutant enzyme DELTA360-329, without tissue factor
1.95
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, activated wild-type enzyme, without tissue factor
44.2
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, plasma derived wild-type enzyme, activated by tissue factor
3.29
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, plasma derived wild-type enzyme, without tissue factor
18.53
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, mutant enzyme which has all of the residues of the loop formed by a disulfide bond between Cys310 and Cys329 replaced with those of trypsin, without tissue factor
37.08
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, activated wild-type enzyme, activated by tissue factor
7.81
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, mutant enzyme DELTA360-329, activated by tissue factor
20.98
D-Ile-Pro-Arg-p-nitroanilide
-
pH 8.0, 30°C, mutant enzyme which has all of the residues of the loop formed by a disulfide bond between Cys310 and Cys329 replaced with those of trypsin, activated by tissue factor
0.8
Factor X
-
mutant enzyme K192A, tissue factor/phosphatidylcholine-phosphatidylserine vesicles
-
7.4
Factor X
-
wild-type enzyme VIIa, tissue factor/phosphatidylcholine-phosphatidylserine vesicles
-
0.05
Factor X
-
mutant enzyme L144A, tissue factor/phosphatidylcholine vesicles
-
0.15
Factor X
-
mutant enzyme L192A or E154A, tissue factor/phosphatidylcholine vesicles
-
0.15
Factor X
-
mutant enzyme L144A, tissue factor/phosphatidylcholine-phosphatidylserine vesicles
-
1.55
Factor X
-
wild-type enzyme VIIa, tissue factor/phosphatidylcholine vesicles
-
0.004
Factor X
wild-type FVIIa + lipidated tissue factor for induced allosteric activation of factor VIIa, pH 7.4
-
1.25
Factor X
-
mutant enzyme E154A, tissue factor/phosphatidylcholine-phosphatidylserine vesicles
-
0.0021
Factor X
mutant G372A + lipidated tissue factor for induced allosteric activation of factor VIIa, pH 7.4
-
0.0027
Factor X
wild-type FVIIa + soluble tissue factor for induced allosteric activation of factor VIIa, pH 7.4
-
0.00001
Factor X
-
in 50 mM HEPES, pH 7.4, with 0.1 M NaCl, 5 mM CaCl2, 0.1% (w/v) bovine serum albumin, and 0.01% Tween 80, at 25°C
-
0.00062
Factor X
mutant G372A + soluble tissue factor for induced allosteric activation of factor VIIa, pH 7.4
-
12.1
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, 37°C, wild-type enzyme
1560
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 6.5, MES buffer, without tissue factor
37.2
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, wild-type enzyme, with addition of tissue factor
47
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, mutant enzyme V21N/E154I/M156Q, with addition of tissue factor
1500
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 6.5, MTE buffer, without tissue factor
24.6
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, 37°C, mutant enzyme M156Q
8.4
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, wild-type enzyme, without tissue factor
32.2
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, mutant enzyme V21N/E154I/M156Q, without tissue factor
49.1
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, 37°C, wild-type enzyme, addition of tissue factor
366000
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 9.5, BTP buffer, in presence of tissue factor
84000
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 9.5, veronal buffer, without tissue factor
246000
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 7.5, Tris buffer, in presence of tissue factor
360000
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 9.5, MTE buffer, in presence of tissue factor
49.8
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 8.0, 37°C, mutant enzyme M156Q, addition of tissue factor
38400
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 7.5, MTE buffer, without tissue factor
31800
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 7.5, Tris buffer, without tissue factor
33600
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 7.5, HEPES buffer, without tissue factor
9600
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 9.5, MTE buffer, without tissue factor
7200
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 9.5, ethanolamine buffer, without tissue factor
5940
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 9.5, BTP buffer, without tissue factor
96000
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 6.5, MES buffer, in presence of tissue factor
96000
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 6.5, MTE buffer, in presence of tissue factor
216000
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 7.5, MTE buffer, in presence of tissue factor
198000
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 7.5, HEPES buffer, in presence of tissue factor
396000
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 9.5, ethanolamine buffer, in presence of tissue factor
324000
N-methylsulfonyl-D-Phe-Gly-Arg-p-nitroanilide
-
pH 9.5, veronal buffer, in presence of tissue factor
additional information
additional information
-
turnover-number of wild-type and mutant enzymes
-
additional information
additional information
-
the ratio of turnover number to KM-value for the substrate methanesulfonyl-D-cyclohexylalanyl-butyl-arginine p-nitroanilide is 25000 for wild-type enzyme, 500 for mutant enzyme V154G and 2500 for mutant enzyme V154A
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
28
D-Ile-Pro-Arg-4-nitroanilide
wild type enzyme, in the presence of soluble tissue factor (1-219), at pH 7.4 and 25°C
0.9
D-Ile-Pro-Arg-4-nitroanilide
wild type enzyme, in the absence of soluble tissue factor (1-219), at pH 7.4 and 25°C
1.4
Factor X
wild-type FVIIa + soluble tissue factor for induced allosteric activation of factor VIIa, pH 7.4
-
0.19
Factor X
mutant G372A + soluble tissue factor for induced allosteric activation of factor VIIa, pH 7.4
-
180
Factor X
mutant G372A + lipidated tissue factor for induced allosteric activation of factor VIIa, pH 7.4
-
270
Factor X
wild-type FVIIa + lipidated tissue factor for induced allosteric activation of factor VIIa
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0004
(2R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
-
pH and temperature not specified in the publication
0.0000052 - 0.00003
(2R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-(propane-2-sulfonyl)-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
0.00000043
(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-7-(cyclopropanesulfonyl)-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo-[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione
-
at pH 7.4 and 37°C
0.00000023
(2R,15R)-2-[(1-amino-7-fluoroisoquinolin-6-yl)amino]-7-(cyclopropanesulfonyl)-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo-[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione
-
at pH 7.4 and 37°C
0.000001
(2R,15R)-2-[(1-amino-8-fluoroisoquinolin-6-yl)amino]-7-(cyclopropanesulfonyl)-4,15,17- trimethyl-13-oxa-4,11-diazatricyclo-[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione
-
at pH 7.4 and 37°C
0.00002
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10-(21),16,19-hexaene-3,12-dione
-
at pH 7.4 and 37°C
0.000015
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11- diazatricyclo[14.2.2.16,10]henicosa-1-(18),6,8,10(21),16,19-hexaene-7-carboxamide
-
at pH 7.4 and 37°C
0.0000055
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-7-(trifluoromethoxy)-13-oxa-4,11-diazatricyclo[14.2.2.16,10]-henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione
-
at pH 7.4 and 37°C
0.0000022
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,20-trimethyl-7-(1-methyl-1H-pyrazol-5-yl)-13-oxa-4,11-diazatricyclo-[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione
-
at pH 7.4 and 37°C
0.00000016
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-(cyclopropanesulfonyl)-4,15,20-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]-henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione
-
at pH 7.4 and 37°C
0.0000025
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-N,N,4,15,17-pentamethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]-henicosa-1(18),6,8,10(21),16,19-hexaene-7-carboxamide
-
at pH 7.4 and 37°C
0.00000057
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-N,N-diethyl-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]-henicosa-1(18),6,8,10(21),16,19-hexaene-7-carboxamide
-
at pH 7.4 and 37°C
0.018 - 0.054
(2S)-2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
0.0000016
(R)-2-(1-aminoisoquinolin-6-ylamino)-7-ethanesulfonyl-20-methyl-4,11-diaza-tricyclo[14.2.2.16,10]henicosa-1(19),6,8,10-(21),16(20),17-hexaene-3,12-dione
-
pH and temperature not specified in the publication
0.000008
(R)-2-(1-aminoisoquinolin-6-ylamino)-7-ethanesulfonyl-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(19),6,8,10(21),16-(20),17-hexaene-3,12-dione
-
pH and temperature not specified in the publication
0.000021
([5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]methyl)propanedioic acid
-
-
0.0046
2-(1-aminoisoquinolin-6-ylamino)-16-oxa-4,11-diazatricyclo-[15.2.2.16,10]docosa-1(20),6,8,10(22),17(21),18-hexaene-3,12-dione trifluoroacetic acid
-
pH and temperature not specified in the publication
0.000004
2-([5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-5'-fluoro-2',6-dihydroxybiphenyl-3-yl]methyl)butanedioic acid
-
-
0.0046 - 0.01
2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[13.2.2.16,10]icosa-1(17),6(20),7,9,15,18-hexaene-3,12-dione
0.00092
2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
-
pH and temperature not specified in the publication
0.0061
2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[15.2.2.16,10]docosa-1(19),6(22),7,9,17,20-hexaene-3,12-dione
-
pH and temperature not specified in the publication
0.000004
2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-5'-fluoro-2',6-dihydroxybiphenyl-3-yl]butanedioic acid
-
-
0.000022
2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]butanedioic acid
-
-
0.000017
2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]pentanedioic acid
-
-
0.000001
2-[5-(5-carbamimidoyl-1H-indol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]butanedioic acid
-
-
0.000036
3-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]pentanedioic acid
-
-
0.000013
3-[5-(5-carbamimidoyl-1H-indol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]pentanedioic acid
-
-
0.0000007
4-((R)-7-ethanesulfonyl-3,12-dioxo-4,11-diaza-tricyclo-[14.2.2.16,10]henicosa-1(19),6,8,10(21),16(20),17-hexaen-2-ylamino)benzamidine trifluoroacetic acid
-
pH and temperature not specified in the publication
0.00000061
diethyl [(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl]phosphonate
-
at pH 7.4 and 37°C
0.0000087
methyl (2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-7-carboxylate
-
at pH 7.4 and 37°C
0.00000035
R-4-[2-(3-aminobenzenesulfonylamino)-1-(3,5-diethoxy-2-fluorophenyl)-2-oxoethylamino]-2-hydroxy-benzamidine
-
0.00000028
[(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,20-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1-(18),6,8,10(21),16,19-hexaen-7-yl](ethoxy)phosphinic acid
-
at pH 7.4 and 37°C
0.000002
[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-5'-fluoro-2',6-dihydroxybiphenyl-3-yl]acetic acid
-
-
0.000015
[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]acetic acid
-
-
0.000003
[5-(5-carbamimidoyl-1H-indol-2-yl)-6-hydroxy-3'-nitrobiphenyl-3-yl]acetic acid
-
-
0.00003
(2R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-(propane-2-sulfonyl)-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
-
pH and temperature not specified in the publication
0.0000052
(2R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-(propane-2-sulfonyl)-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
-
pH and temperature not specified in the publication
0.018
(2S)-2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
-
Ki above 0.018 mM, pH and temperature not specified in the publication
0.054
(2S)-2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
-
pH and temperature not specified in the publication
0.01
2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[13.2.2.16,10]icosa-1(17),6(20),7,9,15,18-hexaene-3,12-dione
-
pH and temperature not specified in the publication
0.0046
2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[13.2.2.16,10]icosa-1(17),6(20),7,9,15,18-hexaene-3,12-dione
-
pH and temperature not specified in the publication
0.1
4-aminobenzamidine
wild-type + soluble tissue factor for induced allosteric activation of factor VIIa
0.7
4-aminobenzamidine
mutant G372 + soluble tissue factor for induced allosteric activation of factor VIIa
3.2
4-aminobenzamidine
-
in 50 mM HEPES, pH 7.4, with 0.1 M NaCl, 5 mM CaCl2, 0.1% (w/v) bovine serum albumin, and 0.01% Tween 80, at 25°C
0.0493
4-aminobenzamidine
wild type enzyme, in the presence of soluble tissue factor (1-219), at pH 7.4 and 25°C
1.485
4-aminobenzamidine
wild type enzyme, in the absence of soluble tissue factor (1-219), at pH 7.4 and 25°C
0.116
p-aminobenzamidine
-
pH 8.0, wild-type enzyme, chromozym tPA as substrate with addition of tissue factor
0.317
p-aminobenzamidine
-
pH 8.0, mutant enzyme V21N/E154I/M156Q, chromozym tPA as substrate without addition of tissue factor
0.124
p-aminobenzamidine
-
pH 8.0, mutant enzyme V21N/E154I/M156Q, chromozym tPA as substrate with addition of tissue factor
additional information
additional information
-
because of competitive binding of p-aminobenzamidine and D-Ile-Pro-Arg-p-nitroanilide, the apparent Ki values were calculated from the p-aminobenzamidine IC50, taking into account the concentration of D-Ile-Pro-Arg-p-nitroanilide ([S]) and the Km for this substrate using Ki =IC50/(1 + [S]/Km)
-
additional information
additional information
-
inhibition kinetics of wild-type and mutant enzymes, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.00034
2-(3'-amino-3-fluoro-4-(isopropylamino)-1,1'-biphenyl-2-yl)-N-(4-(amino(imino)methyl)benzyl)acetamide
Homo sapiens
-
IC50: 340 nM
0.0005
2-(3'-amino-4-(benzylamino)-3-fluoro-1,1'-biphenyl-2-yl)-N-(4-(amino(imino)methyl)benzyl)acetamide
Homo sapiens
-
IC50: 500 nM
0.0007
2-(3-allylamino-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 700 nM
0.00077
2-(3-benzylamino-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 770 nM
0.0064
2-(3-benzylsulfanyl-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0064 mM
0.0032
2-(3-butylamino-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl)-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0032 mM
0.0021
2-[3-(2-amino-ethylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0021 mM
0.00089
2-[3-(3-amino-propylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 890 nM
0.00098
2-[3-(4-amino-butylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 980 nM
0.003
2-[3-(4-tert-butyl-cyclohexylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.003 mM
0.013
2-[3-(adamantan-1-ylamino)-5-chloro-2-oxo-6-phenyl-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.013 mM
0.00161
2-[6-(3-acetylamino-phenyl)-5-chloro-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.00161 mM
0.00007
2-[6-(3-amino-phenyl)-5-chloro-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 70 nM
0.00002
2-[6-(3-amino-phenyl)-5-chloro-3-cyclobutylamino-2-oxo-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 20 nM
0.00002
2-[6-(3-amino-phenyl)-5-chloro-3-isopropylamino-2-oxo-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 20 nM
0.0042
2-[6-(3-bromo-phenyl)-5-chloro-3-cyclobutylamino-2-oxo-2H-pyrazin-1-yl]-N-(4-carbamimidoyl-benzyl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0042 mM
0.000039
3-(3-[(R)-2-[(S)-1-(4-carbamimidoyl-benzylcarbamoyl)-3-carbamoylpropylcarbamoyl]-2-ethanesulfonylamino-ethyl]-1H-indol-5-yloxymethyl)-benzoic acid
Homo sapiens
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.000118
3-amino-5-(1-(1-((4-(amino(imino)methyl)benzyl)-amino)-2-oxoethyl)-5-(isopropylamino)-6-oxo-1,6-dihydropyridin-2-yl)benzoic acid
Homo sapiens
-
IC50: 118 nM
0.000016
3-amino-5-[1-[2-([4-[amino(imino)methyl]benzyl]amino)-2-oxoethyl]-3-chloro-5-(isopropylamino)-6-oxo-1,6-dihydropyrazin-2-yl]benzoic acid
Homo sapiens
-
pH 8.0, IC50: 16 nM, potent and highly selective inhibitor, selectivity versus factor Xa and thrombin
0.0003
3-methyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-pentanoic acid [4-guanidino-1-(thiazole-2-carbonyl)-butyl]-amide
Homo sapiens
-
IC50: 300 nM, reversible, covalent
0.00145
3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00145 mM, reversible, covalent
0.00036
3-[1-[(4-carbamimidoyl-benzylcarbamoyl)-methyl]-3-chloro-5-isopropylamino-6-oxo-1,6-dihydro-pyrazin-2-yl]-benzoic acid
Homo sapiens
-
pH 8.0, IC50: 360 nM
0.00078
3-[1-[(4-carbamimidoyl-benzylcarbamoyl)-methyl]-3-chloro-5-isopropylamino-6-oxo-1,6-dihydro-pyrazin-2-yl]-benzoic acid methyl ester
Homo sapiens
-
pH 8.0, IC50: 780 nM
0.0007
4,4-dimethyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-pentanoic acid [4-guanidino-1-(thiazole-2-carbonyl)-butyl]-amide
Homo sapiens
-
IC50: 700 nM, reversible, covalent
0.000204
5-(4-carboxybutoxy)-N-(ethylsulfonyl)-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
Homo sapiens
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.000056
5-[(3-carboxybenzyl)oxy]-N-(ethylsulfonyl)-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
Homo sapiens
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.00282
6-dimethylamino-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-hexanoic acid [4-guanidino-1-(thiazole-2-carbonyl)-butyl]-amide
Homo sapiens
-
IC50: 0.00282 mM, reversible, covalent
0.0024
D-prolyl-N-(4-carbamimidoylbenzyl)-L-prolinamide
Homo sapiens
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.00000023
EEWEVLCWTWETCERGEGVEEELWEWR
Homo sapiens
-
maximal inhibition to 99%, IC50: 230 pM
0.019
FFR-FVIIa
Homo sapiens
-
derivate of FVIIa with a stably buried N-terminus representing the active conformation of FVIIa, IC50: 0.019 mM
-
0.00045
N-(3-[1-[(4-carbamimidoyl-benzylcarbamoyl)-methyl]-3-chloro-6-oxo-5-phenethylamino-1,6-dihydro-pyrazin-2-yl]-phenyl)-2,2,2-trifluoro-acetamide
Homo sapiens
-
pH 8.0, IC50: 450 nM
0.0164
N-(4-(amino(imino)methyl)benzyl)-2-(2,6-difluoro-3-((2-phenylethyl)amino)phenyl)acetamide
Homo sapiens
-
IC50: 0.0164 mM
0.00398
N-(4-(amino(imino)methyl)benzyl)-2-(3-fluoro-4-((2-phenylethyl)amino)-1,1'-biphenyl-2-yl)acetamide
Homo sapiens
-
IC50: 0.00398 mM
0.0027
N-(4-(amino(imino)methyl)benzyl)-2-(3-hydroxy-4-((2-phenylethyl)amino)-1,1'-biphenyl-2-yl)acetamide
Homo sapiens
-
IC50: 0.0027 mM
0.0025
N-(4-(amino(imino)methyl)benzyl)-2-(3-hydroxy-4-(isopropylamino)-1,1'-biphenyl-2-yl)acetamide
Homo sapiens
-
IC50: 0.0025 mM
0.025
N-(4-(amino(imino)methyl)benzyl)-2-(3-methoxy-4-((2-phenylethyl)amino)-1,1'-biphenyl-2-yl)acetamide
Homo sapiens
-
IC50: 0.025 mM
0.0147
N-(4-(amino(imino)methyl)benzyl)-2-(4-(isopropylamino)-3-methoxy-1,1'-biphenyl-2-yl)acetamide
Homo sapiens
-
IC50: 0.0147 mM
0.0028
N-(4-(amino(imino)methyl)benzyl)-2-(5-(isopropylamino)-3,6-dioxo-2-phenylcyclohexa-1,4-dien-1-yl)acetamide
Homo sapiens
-
IC50: 0.0028 mM
0.000052
N-(4-(amino(imino)methyl)benzyl)-2-(6-(3,5-diaminophenyl)-3-(isopropylamino)-2-oxopyridin-1(2H)-yl)acetamide
Homo sapiens
-
IC50: 52 nM
0.00034
N-(4-carbamimidoyl-benzyl)-2-(2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 340 nM
0.001
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-m-tolyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.001 mM
0.00043
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-o-tolyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 430 nM
0.00414
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-p-tolyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.00414 mM
0.00063
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 630 nM
0.0112
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-phenylamino-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0112 mM
0.00072
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-prop-2-ynylamino-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 720 nM
0.0004
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-propylamino-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 400 nM
0.0063
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-2-oxo-6-phenyl-3-pyrrolidin-1-yl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0063 mM
0.0004
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-cyclobutylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 400 nM
0.0014
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-cyclohexylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0014 mM
0.0004
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-ethylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 400 nM
0.0002
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-isopropylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 200 nM
0.0007
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-3-methylamino-2-oxo-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 700 nM
0.00345
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-6-ethyl-2-oxo-3-phenethylamino-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.00345 mM
0.00428
N-(4-carbamimidoyl-benzyl)-2-(5-chloro-6-methyl-2-oxo-3-phenethylamino-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.00428 mM
0.0027
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-3-phenethylamino-6-(2-trifluoromethyl-phenyl)-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0027 mM
0.0029
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-3-phenethylamino-6-(3-trifluoromethyl-phenyl)-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0029 mM
0.0018
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(1-propyl-butylamino)-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0018 mM
0.0126
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(3-phenyl-propylamino)-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0126 mM
0.0063
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(3-trifluoromethyl-benzylamino)-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0063 mM
0.0041
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-2-oxo-6-phenyl-3-(4-phenyl-butylamino)-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0041 mM
0.001
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1,1-dioxo-tetrahydro-16-thiophen-3-ylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.001 mM
0.0098
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-ethyl-hexylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0098 mM
0.00043
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-ethyl-propylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 430 nM
0.00084
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-methyl-butylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 840 nM
0.0009
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(1-methyl-pentylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 900 nM
0.0038
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2,5-difluoro-benzylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0038 mM
0.0209
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-dimethylamino-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0209 mM
500
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-hydroxy-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 500 mM
880
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-methoxy-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 880 mM
0.008
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(2-morpholin-4-yl-ethylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.008 mM
0.006
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(3,5-difluoro-benzylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.006 mM
0.0176
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(3-dimethylamino-propylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0176 mM
0.0005
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(3-hydroxy-propylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 500 nM
0.0043
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(4-chloro-benzylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0043 mM
0.0006
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(4-hydroxy-butylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 600 nM
0.00047
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(6-hydroxy-hexylamino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 470 nM
0.0091
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-(isopropyl-methyl-amino)-2-oxo-6-phenyl-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0091 mM
0.00034
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-cyclobutylamino-6-(2-hydroxy-phenyl)-2-oxo-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 340 nM
0.0002
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-3-cyclobutylamino-6-(3-hydroxy-phenyl)-2-oxo-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 200 nM
0.003
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(2-chloro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.003 mM
0.0018
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(2-fluoro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0018 mM
0.0016
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(2-methoxy-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0016 mM
0.00198
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-chloro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.00198 mM
0.0012
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-dimethylamino-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0012 mM
0.0023
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-fluoro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0023 mM
0.0006
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-methanesulfonylamino-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 600 nM
0.0052
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-methoxy-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0052 mM
0.0006
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-methylamino-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 600 nM
0.00252
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(3-nitro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.00252 mM
0.00888
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(4-chloro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.00888 mM
0.0081
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(4-fluoro-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0081 mM
0.02345
N-(4-carbamimidoyl-benzyl)-2-[5-chloro-6-(4-methoxy-phenyl)-2-oxo-3-phenethylamino-2H-pyrazin-1-yl]-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.02345 mM
0.03
N-(4-carbamimidoyl-benzyl)-2-{5-chloro-2-oxo-6-phenyl-3-[2-(3-trifluoromethyl-phenyl)-ethylamino]-2H-pyrazin-1-yl}-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.03 mM
0.00018
N-(4-carbamimidoyl-benzyl)-2-{5-chloro-3-[2-(3-chloro-phenyl)-ethylamino]-2-oxo-6-phenyl-2H-pyrazin-1-yl}-acetamide
Homo sapiens
-
pH 8.0, IC50: 180 nM
0.0006
N-(4-carbamimidoyl-benzyl)-2-{5-chloro-3-[2-(4-chloro-phenyl)-ethylamino]-2-oxo-6-phenyl-2H-pyrazin-1-yl}-acetamide
Homo sapiens
-
pH 8.0, IC50: 600 nM
0.0167
N-(5-carbamimidoyl-pyridin-2-ylmethyl)-2-(2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0167 mM
0.0014
N-(6-carbamimidoyl-pyridin-3-ylmethyl)-2-(2-oxo-3-phenethylamino-6-phenyl-2H-pyrazin-1-yl)-acetamide
Homo sapiens
-
pH 8.0, IC50: 0.0014 mM
0.000069
N-(ethylsulfonyl)-1-methyl-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
Homo sapiens
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.00014
N-(ethylsulfonyl)-5-hydroxy-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
Homo sapiens
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.000065
N-(ethylsulfonyl)-5-methoxy-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-D-glutamamide
Homo sapiens
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.000062
N-(ethylsulfonyl)-D-tryptophyl-N1-(4-carbamimidoylbenzyl)-L-glutamamide
Homo sapiens
in 500 mM Tris-HCl, pH 7.5, 1.5 M NaCl, 50 mM CaCl2, temperature not specified in the publication
0.0002
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(3,4,5-trifluoro-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 200 nM, reversible, covalent
0.0008
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(3-trifluoromethyl-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 800 nM, reversible, covalent
0.00156
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(4-iodo-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00156 mM, reversible, covalent
0.00588
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-(4-nitro-phenyl)-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00588 mM, reversible, covalent
0.00011
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-hydroxy-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 110 nM, reversible, covalent
0.00017
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-m-tolyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 170 nM, reversible, covalent
0.0056
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-naphthalen-1-yl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.0056 mM, reversible, covalent
0.00195
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-naphthalen-2-yl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00195 mM, reversible, covalent
0.00024
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-o-tolyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 240 nM, reversible, covalent
0.00129
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-p-tolyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00129 mM, reversible, covalent
0.000042
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-phenyl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 42 nM, reversible, covalent
0.0002
N-[1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-pyridin-3-yl-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 200 nM, reversible, covalent
0.00997
N-[2-(1-benzyl-1H-imidazol-4-yl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00997 mM, reversible, covalent
0.0007
N-[2-(2,6-dimethyl-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 700 nM, reversible, covalent
0.00009
N-[2-(2-fluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 90 nM, reversible, covalent
0.00016
N-[2-(3,4-difluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 160 nM, reversible, covalent
0.00019
N-[2-(3,5-difluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 190 nM, reversible, covalent
0.00023
N-[2-(3-chloro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 230 nM, reversible, covalent
0.0002
N-[2-(3-fluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 200 nM, reversible, covalent
0.00057
N-[2-(4-acetylamino-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 570 nM, reversible, covalent
0.00076
N-[2-(4-bromo-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 760 nM, reversible, covalent
680
N-[2-(4-chloro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 680 mM, reversible, covalent
0.00034
N-[2-(4-cyano-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 340 nM, reversible, covalent
0.00017
N-[2-(4-fluoro-phenyl)-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 170 nM, reversible, covalent
0.0005
N-[2-benzo[b]thiophen-3-yl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.0005 mM, reversible, covalent
0.00153
N-[2-benzyloxy-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00153 mM, reversible, covalent
0.00183
N-[2-biphenyl-3-yl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.00183 mM, reversible, covalent
0.0178
N-[2-biphenyl-4-yl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.0178 mM, reversible, covalent
0.0033
N-[2-cyclohexyl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 0.0033 mM, reversible, covalent
0.00082
N-[2-cyclopropyl-1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-ethyl]-3-phenyl-2-phenylmethanesulfonylamino-propionamide
Homo sapiens
-
IC50: 820 nM, reversible, covalent
0.00318
N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-3-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-succinamic acid cyclohexyl ester
Homo sapiens
-
IC50: 0.00318 mM, reversible, covalent
0.0137
N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-4-methanesulfonyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-butyramide
Homo sapiens
-
IC50: 0.0137 mM, reversible, covalent
0.0009
N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-4-phenyl-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-butyramide
Homo sapiens
-
IC50: 900 nM, reversible, covalent
0.00103
N1-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-2-(3-phenyl-2-phenylmethanesulfonylamino-propionylamino)-succinamide
Homo sapiens
-
IC50: 0.00103 mM, reversible, covalent
0.014
V154G-FVIIa
Homo sapiens
-
derivate of FVIIa with a fully exposed N-terminus representing the zymogen-like conformation of FVIIa, IC50: 0.014 mM
-
0.0000016
EEWEVLCWTWETCER
Homo sapiens
-
IC50: 1.6 nM, partial hyperbolic mixed-type inhibitor of factor X activation, partial competitive inhibitor of amidolytic activity. Inhibits activation of factor X and factor IX and amidolytic activity of Chromozym t-PA with IC50 values of 1.6 nM, 3.5 nM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
additional information
-
catalytic efficiencies of wild-type and mutant enzymes with different substrates, overview
additional information
-
enzyme activity in the circadian clock machinery, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
7.4
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
5 - 40
-
5°C: about 90% of maximal activity, 40°C: about 50% of maximal activity, cleavage of Ile-Pro-Arg-p-nitroanilide
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
95336, 654496, 654508, 654583, 654595, 654613, 654639, 654663, 656000, 656015, 656025, 656033, 656136, 656462, 656463, 656464, 656465
-
-
brenda
-
657181, 657312, 657378, 657386, 667430, 667474, 667584, 667588, 667668, 667680, 668158, 668259, 668304, 669415
-
-
brenda
-
669484, 670270, 670935, 683139, 683297, 683298, 683347, 683477, 683855, 683996, 684040, 684070, 692003, 692535, 695182, 707073, 707149
-
-
brenda
-
-
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
-
Ca2+ and the Gla domain are required for membrane binding by the enzyme, mechanism of Ca2+-mediated binding, molecular dynamics simulation of complex formation, overview
-
brenda
-
the major function of the enzyme's Gla domain is to attach FVIIa to membranes, i.e. to add binding energy to the interaction with membrane-associated tissue factor
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
physiological function
malfunction
physiological function
-
chronic sleep deprivation in a mouse model reduces, in a reversible manner, the FVII expression levels and activity level, thus influencing the TF/FVIIa activation pathway efficiency
physiological function
-
surface plasmon resonance results show that recombinant factor VII can depress the integration of EGFP-EGF1 (fusion protein epidermal growth factor 1-enhanced green fluorescent protein) with recombinant tissue factor
physiological function
-
this study investigates the evolutionary history of F7 variation in human populations from the broader Mediterranean region and other parts of the world. Different evolutionary histories in the F7 promoter region between Mediterraneans and Amerindians are indicated
physiological function
-
following injection in mice, both hepatocytes and Kupffer cells appear to be involved in the hepatic clearance and metabolism of both full-length recombinant factor VIIa and recombinant factor VIIa in complex with at least two plasma protease inhibitors
physiological function
FVIIa in complex with tissue factor initiates the extrinsic coagulation pathway
physiological function
-
hepatocytes and Kupffer cells and possibly sinusoidal endothelial cells of the rat liver are shown to be physiologically relevant for the clearance of pharmacological doses of recombinant factor FVIIa in rats
physiological function
-
tissue factor-factor VIIa increases interleukin-8 release, decreases caspase-7 expression, enhances tissue factor expression, and suppresses the phosphorylation of p38MAPK in SW-620 cells through protease-activated receptor-2 activation thereby promoting colon cancer cell proliferation and migration
physiological function
-
factor VIIa induces cell survival and gene transcription by transactivation of the insulin-like growth factor 1 receptor. Binding of coagulation factor VIIa to ist receptor tissue factor protects cancer cells from TNF-related apoptosis inducing ligand-induced apoptosis
physiological function
-
FVIIa causes potentiation of cell repulsion by the Eph tyrosine kinase receptor EphB2 ligand ephrin-B1, demonstrating a proteolytical event to control Eph-mediated cell segregation
physiological function
-
factor VIIa-induced interaction with integrin controls the release of tissue factor on extracellular vesicles from endothelial cells. Intracellular trafficking controlled by factor FVIIa forcing interaction with integrin beta1 regulates tissue factor availability for release on procoagulant extracellular vesicles
physiological function
the complex of coagulation factor VIIa and membrane-bound tissue factor initiates blood coagulation upon vascular injury
physiological function
-
tissue factor facilitates the activation of the enzyme thereby initiating the extrinsic coagulation pathway followed by the activation of factor X and thrombin formation. The enzyme functions in blood coagulation and maintenance of the hemostatic balance in the vasculature. The tissue factor:factor VIIa complex is one of the triggers of PAR-2 activation. The tissue factor:factorVIIa pathway is also implicated in the onset of cardiac fibrosis
physiological function
-
tissue factor/coagulation factor VIIa-EphA2 cross-talk potentiates ligand-dependent EphA2 signaling in human cancers. Tissue factor and EphA2 co-localize constitutively in MDA-MB-231 cells, and addition of enzyme results in cleavage of EphA2 by a protease activated receptor 2-independent mechanism
malfunction
-
eosinophil counts in the bronchoalveolar lavage fluid of wild-type mice increases after ovalbumin challenge, a response that is diminished in comparably challenged low-expressing coagulation factor VII (FVIItTA/tTA) mice. Levels of T helper type 2 cytokines, IL-4, IL-5, and IL-13, and eosinophil-attracting chemokines, eotaxin and RANTES, are also lower in the ovalbumin-challenged low expression factor VIIa mice. Eosinophils purified from low-FVII mice undergo apoptosis at a faster rate compared with wild-type eosinophils, and eosinophil migration in response to eotaxin is reduced in eosinophils obtained from low expressing factor VIIa mice. Airway hyperresponsiveness and mucous layer thickness are reduced in ovalbumin-treated low expressing factor VIIa mice
malfunction
-
the small nuclear RNA-U1 (U1+ 5a) mediated rescue of FVII mRNA processing impaired by the 9726 + 5G to A mutation results in an appreciable secretion of functional FVII
Show AA Sequence and Transmembrane Helices (490 entries)
Please use the AA Sequence and Transmembrane Helices Search for a specific query.
Please use the AA Sequence and Transmembrane Helices Search for a specific query.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
5pas,